SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.219
AS - Asia 1.665
EU - Europa 686
SA - Sud America 394
AF - Africa 36
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.006
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.150
SG - Singapore 769
CN - Cina 371
BR - Brasile 332
IT - Italia 205
HK - Hong Kong 189
VN - Vietnam 131
DE - Germania 99
GB - Regno Unito 74
TR - Turchia 54
RU - Federazione Russa 52
UA - Ucraina 51
PL - Polonia 50
SE - Svezia 35
CA - Canada 34
FI - Finlandia 33
MX - Messico 29
AR - Argentina 28
FR - Francia 28
IN - India 27
ID - Indonesia 25
ZA - Sudafrica 23
BD - Bangladesh 19
NL - Olanda 19
JP - Giappone 14
UZ - Uzbekistan 12
AT - Austria 11
EC - Ecuador 11
CZ - Repubblica Ceca 8
IQ - Iraq 8
PK - Pakistan 8
CO - Colombia 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
ES - Italia 5
PH - Filippine 5
KR - Corea 4
LT - Lituania 4
AU - Australia 3
CL - Cile 3
KE - Kenya 3
PE - Perù 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
DZ - Algeria 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KH - Cambogia 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
IE - Irlanda 1
IR - Iran 1
KW - Kuwait 1
KZ - Kazakistan 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
RS - Serbia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 6.006
Salva come PNG Salva come JPEG
Città #
Dallas 1.011
Singapore 398
Ashburn 347
Santa Clara 197
Hong Kong 189
Beijing 170
Chandler 138
Fairfield 138
Houston 99
Ann Arbor 93
Ferrara 90
Woodbridge 85
Los Angeles 81
Jacksonville 54
Seattle 51
Wilmington 51
Ho Chi Minh City 50
Warsaw 49
Princeton 46
Cambridge 44
New York 34
Munich 33
Buffalo 31
São Paulo 31
Izmir 25
Shanghai 24
Chicago 23
Hanoi 22
Jakarta 21
London 18
San Diego 18
Bologna 15
Brooklyn 15
Chennai 15
Mexico City 14
Milan 14
Nuremberg 14
Tokyo 14
Nanjing 13
Stockholm 13
Turku 13
Johannesburg 12
Washington 12
Redondo Beach 11
Tashkent 11
Manchester 10
Montreal 10
Toronto 10
Boardman 9
Changsha 9
Falls Church 9
Helsinki 9
Orem 9
Phoenix 9
Poplar 9
Atlanta 8
Brno 8
Curitiba 8
Denver 8
Rio de Janeiro 8
Amsterdam 7
Frankfurt am Main 7
Hefei 7
The Dalles 7
Boston 6
Salvador 6
Belo Horizonte 5
Brasília 5
Brussels 5
Calgary 5
Council Bluffs 5
Da Nang 5
Guayaquil 5
Hải Dương 5
Osasco 5
Padova 5
Redmond 5
San Francisco 5
Secaucus 5
Assago 4
Asunción 4
Baghdad 4
Charlotte 4
Dhaka 4
Ferrara di Monte Baldo 4
Goiânia 4
Haiphong 4
Lahore 4
Las Vegas 4
Manassas 4
Manila 4
Molinella 4
Norwalk 4
Pelotas 4
Porto Alegre 4
Querétaro 4
Ribeirão Preto 4
San Giorgio delle Pertiche 4
San Jose 4
São José do Rio Preto 4
Totale 4.169
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 840
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 241
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 228
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 227
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 180
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 166
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 156
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 151
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 151
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 123
null 118
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 112
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 109
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 103
A QM/MM study of the binding of RAPTA ligands to cathepsin B 100
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 99
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 93
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 93
null 90
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 87
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 86
Aquaporin inhibition by gold(III) compounds: New insights 85
Activation of carboplatin by carbonate: A theoretical investigation 85
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 84
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 84
Advances in Computational Techniques to Study GPCR-Ligand Recognition 81
Activation of carboplatin by chloride ions: a theoretical investigation 78
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 75
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 75
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 75
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 73
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 72
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 71
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 69
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 69
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 65
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 64
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 64
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 63
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 63
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 61
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 61
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 60
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 60
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 58
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 58
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 57
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 56
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 56
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 54
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 53
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 53
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 51
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 48
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 48
Enhancing torsional sampling using fully adaptive simulated tempering 48
Implementing the “Best Template Searching” tool into Adenosiland platform 47
Polypharmacology of conformationally locked methanocarba nucleosides 44
In silico 3D modeling of binding activities 43
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 39
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 37
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 35
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 31
P2Y14 Receptor 25
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 21
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 6
Totale 6.158
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.445
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.792
Totale 38.237
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 24 7 25 16 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20263.167 394 383 1.139 452 621 178 0 0 0 0 0 0
Totale 6.158